Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled Crossover Study to Explore the Effects of ACD440 in Patients With Peripheral Neuropathic Pain With Sensory Hypersensitivity

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACD 440 (Primary)
Indications Neuropathic pain; Polyneuropathy; Postherpetic neuralgia
Focus Therapeutic Use
Sponsors AlzeCure

Most Recent Events

12 Oct 2023 According to a AlzeCure media release, data from this study were presented at the pain conference held by the Swedish Pain Society.
12 Oct 2023 Results presented in the AlzeCure Media Release.
20 Sep 2023 Results presented in the AlzeCure Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com